MP08-17 BLUE LIGHT CYSTOSCOPY IMPROVES DETECTION RATES FOR UROTHELIAL BLADDER CANCER COMPARED TO WHITE LIGHT CYSTOSCOPY: UPDATED RESULTS FROM A PROSPECTIVE MULTICENTER REGISTRY

You have accessJournal of UrologyBladder Cancer: Non-invasive I1 Apr 2018MP08-17 BLUE LIGHT CYSTOSCOPY IMPROVES DETECTION RATES FOR UROTHELIAL BLADDER CANCER COMPARED TO WHITE LIGHT CYSTOSCOPY: UPDATED RESULTS FROM A PROSPECTIVE MULTICENTER REGISTRY Shane Pearce, Zhoobin Bateni, Soroush Bazargani, Trinity Bivalacqua, Kamal Pohar, Badrinath Konety, John Fitzgerald, T. Brian Willard, Jennifer Taylor, Joseph Liao, Jeffrey Holzbeierlein, John Taylor, James Tierney, Maxwell Meng, Sima Porten, Kirsten Greene, Hooman Djaladat, Anne Schuckman, and Siamak Daneshmand Shane PearceShane Pearce More articles by this author , Zhoobin BateniZhoobin Bateni More articles by this author , Soroush BazarganiSoroush Bazargani More articles by this author , Trinity BivalacquaTrinity Bivalacqua More articles by this author , Kamal PoharKamal Pohar More articles by this author , Badrinath KonetyBadrinath Konety More articles by this author , John FitzgeraldJohn Fitzgerald More articles by this author , T. Brian WillardT. Brian Willard More articles by this author , Jennifer TaylorJennifer Taylor More articles by this author , Joseph LiaoJoseph Liao More articles by this author , Jeffrey HolzbeierleinJeffrey Holzbeierlein More articles by this author , John TaylorJohn Taylor More articles by this author , James TierneyJames Tierney More articles by this author , Maxwell MengMaxwell Meng More articles by this author , Sima PortenSima Porten More articles by this author , Kirsten GreeneKirsten Greene More articles by this author , Hooman DjaladatHooman Djaladat More articles by this author , Anne SchuckmanAnne Schuckman More articles by this author , and Siamak DaneshmandSiamak Daneshmand More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.322AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Blue light cystoscopy (BLC) with hexaminolevulinate (Cysview) when utilized in transurethral resection of bladder tumors (TURBT), increases detection and reduces recurrence rates of non-muscle invasive bladder cancer (NMIBC). We report updated results from an ongoing prospective multicenter registry. METHODS From April 2014 to October 2017, patients from 9 different centers undergoing TURBT for NMIBC were enrolled in a prospective registry. All lesions were assessed using BLC and white light cystoscopy (WLC). Flat lesions were defined as lesions with a flat appearance or appearance consistent with carcinoma-in-situ. Sensitivity and specificity of cystoscopic assessment was determined by comparison to the gold-standard pathologic diagnosis of the individual lesions. RESULTS A total of 749 patients underwent 933 TURBT and 2,268 separate lesions were identified and resected. Mean age was 73 years and 83% were male. For detection of any malignancy, the sensitivity of BLC (91%) was higher than WLC (79%, p<0.001) and the combination had a sensitivity of 99%. The improved detection rate of any malignancy was notable for flat lesions (BLC 91% vs. WLC 64%, p<0.001). The sensitivity of BLC was also higher for patients with previous BCG treatment (p<0.001). BLC outperformed WLC for all TURBT indications including abnormal cytology. BLC had higher sensitivity compared to WLC for all topographic regions of the bladder; however, the positive predictive value (PPV) of BLC was reduced to 58% for lesions in the prostatic urethra, bladder neck, or trigone compared to 66% PPV for lesions on the anterior, posterior, lateral wall or dome. The number needed to screen with BLC for the diagnosis of an additional malignant lesion was 5. 307 patients had lesions only visible on BLC and 29 of these patients underwent radical cystectomy including 4 patients with tumors identified solely on BLC. CONCLUSIONS BLC improves detection rates for NMIBC, particularly for flat appearing lesions. The number needed to screen for the diagnosis of an additional malignant lesion was 5. Improved detection rates for BLC are maintained for all TURBT indications and all topographic locations within the bladder. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e102-e103 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Shane Pearce More articles by this author Zhoobin Bateni More articles by this author Soroush Bazargani More articles by this author Trinity Bivalacqua More articles by this author Kamal Pohar More articles by this author Badrinath Konety More articles by this author John Fitzgerald More articles by this author T. Brian Willard More articles by this author Jennifer Taylor More articles by this author Joseph Liao More articles by this author Jeffrey Holzbeierlein More articles by this author John Taylor More articles by this author James Tierney More articles by this author Maxwell Meng More articles by this author Sima Porten More articles by this author Kirsten Greene More articles by this author Hooman Djaladat More articles by this author Anne Schuckman More articles by this author Siamak Daneshmand More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...